scholarly journals The bone flare phenomenon during the treatment of bone metastases of lung adenocarcinoma

2021 ◽  
Author(s):  
Jianhua Shi ◽  
Guimin Chen ◽  
Tianhui Xu ◽  
Xiuxiu Wang ◽  
Junxia Ruan ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Adenocarcinoma ◽  
Bone Metastases ◽  
Serum Alkaline Phosphatase ◽  
Bone Lesion ◽  
Combined Chemotherapy ◽  
Bone Change ◽  
Tumor Treatment ◽  
Flare Phenomenon ◽  
Dual Drug

Abstract Background The bone flare phenomenon, defined as an increase in bone lesion activity, is a kind of benign bone change in response to ongoing tumor treatment. The purpose of this study was to investigate the time, incidence, and clinical significance of bone flare in lung adenocarcinoma patients with bone metastases, as well as to observe the levels of serum alkaline phosphatase ALP and serum calcium Ca^2+ in patients with bone flare phenomenon.Methods Fifty-seven patients with advanced lung adenocarcinoma who participated in the anti-tumor clinical trials from December 2017 to December 2019 in Linyi Cancer Hospital were included in the study. The CT (computed tomography, CT) images, serum ALP and Ca^2+ from all patients were analyzed retrospectively.Results Among a total of 57 patients, 28 were male, and 29 were female. The median age was 62 years (33–75 years), and 30 of them had bone metastases at baseline. Forty-six EGFR negative patients received platinum-based dual-drug chemotherapy or bevacizumab or combined with PD-1 antibody inhibitors, and 11 EGFR positive patients received targeted EGFR inhibitors. The bone flare was detected in 7 out of 30 patients with bone metastases at baseline (5 patients in the combined chemotherapy group and two patients in the targeted treatment group). The incidence of bone flare was 23.33% (7 / 30). The median time was 45 days after treatment (from 41 days to 120 days), and most of them occurred in the early stages of the treatment.

scholarly journals Two Cases of the Alkaline Phosphatase Flare Phenomenon Following the Administration of Gefitinib Therapy in Patients with Lung Adenocarcinoma with Bone Metastases

Haigan ◽  
2013 ◽  
Vol 53 (4) ◽  
pp. 329-335 ◽  
Author(s):  
Masami Kameda ◽  
Koji Kuronuma ◽  
Satsuki Miyajima ◽  
Hirofumi Chiba ◽  
Gen Yamada ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Lung Adenocarcinoma ◽  
Bone Metastases ◽  
Flare Phenomenon

Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer

2020 ◽  
Vol 16 (5) ◽  
pp. 565-571
Author(s):  
Jinguo Zhang ◽  
Guanzhong Zhai ◽  
Bin Yang ◽  
Zhenhe Liu
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Bone Metastases ◽  
Computerized Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Major Complication ◽  
Tracer Uptake ◽  
Emission Computed Tomography ◽  
Pet Ct

Prostate cancer is one of the most common cancers in men. This cancer is often associated with indolent tumors with little or no lethal potential. Some of the patients with aggressive prostate cancer have increased morbidity and early deaths. A major complication in advanced prostate cancer is bone metastasis that mainly results in pain, pathological fractures, and compression of spinal nerves. These complications in turn cause severe pain radiating to the extremities and possibly sensory as well as motor disturbances. Further, in patients with a high risk of metastases, treatment is limited to palliative therapies. Therefore, accurate methods for the detection of bone metastases are essential. Technical advances such as single-photon emission computed tomography/ computed tomography (SPECT/CT) have emerged after the introduction of bone scans. These advanced methods allow tomographic image acquisition and help in attenuation correction with anatomical co-localization. The use of positron emission tomography/CT (PET/CT) scanners is also on the rise. These PET scanners are mainly utilized with 18F-sodium-fluoride (NaF), in order to visualize the skeleton and possible changes. Moreover, NaF PET/CT is associated with higher tracer uptake, increased target-to-background ratio and has a higher spatial resolution. However, these newer technologies have not been adopted in clinical guidelines due to lack of definite evidence in support of their use in bone metastases cases. The present review article is focused on current perspectives and challenges of computerized tomography (CT) applications in cases of bone metastases during prostate cancer.

scholarly journals MA02.08 Computed Tomography Attenuation Value as Considerable Predictor for Malignancy in Clinical T1 Lung Adenocarcinoma

2021 ◽  
Vol 16 (3) ◽  
pp. S135-S136
Author(s):  
Z. Qiu ◽  
C. Zhang ◽  
H. Wang ◽  
R. Fu ◽  
F. Cai ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Adenocarcinoma ◽  
Attenuation Value

scholarly journals Alkaline phosphatase flare with hyperostosis of bone metastases in lung adenocarcinoma treated with gefitinib

2017 ◽  
Vol 3 (2) ◽  
pp. 34
Author(s):  
Hiroto Kaneko ◽  
Kazuho Shimura ◽  
Yosuke Matsumoto ◽  
Mihoko Yoshida ◽  
Masafumi Taniwaki ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Lung Adenocarcinoma ◽  
Bone Metastases

Air-Containing Space in Lung Adenocarcinoma: High-Resolution Computed Tomography Findings

2002 ◽  
Vol 26 (6) ◽  
pp. 1026-1031 ◽  
Author(s):  
Atsushi Nambu ◽  
Kazuyuki Miyata ◽  
Katsura Ozawa ◽  
Masahisa Miyazawa ◽  
Yuuko Taguchi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
High Resolution ◽  
Lung Adenocarcinoma ◽  
High Resolution Computed Tomography

Features Based on Thin-section Computed Tomography Identify the Typeof lung Adenocarcinoma

2020 ◽  
Author(s):  
Zhiqiang Li ◽  
Hongwei Zheng ◽  
Shanshan Liu ◽  
Xinhua Wang ◽  
Lei Xiao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Adenocarcinoma ◽  
Thin Section ◽  
Ground Glass Opacity ◽  
Smoking History ◽  
Ground Glass ◽  
Quantitative Aspect ◽  
Adenocarcinoma In Situ ◽  
Invasive Adenocarcinoma ◽  
Pleural Invasion

Abstract Background: To investigate whether thin-section computed tomography (TSCT) features may efficiently guide the invasiveness basedclassification of lung adenocarcinoma. Methods: Totally, 316 lung adenocarcinoma patients (from 2011-2015) were divided into three groups: 56 adenocarcinoma in situ (AIS), 98 minimally invasive adenocarcinoma (MIA), and 162 invasive adenocarcinoma (IAC) according their pathological results. Their TSCT features, including nodule pattern, shape, pleural invasion, solid proportion, border, margin, vascular convergence, air bronchograms, vacuole sign, pleural indentation, diameter, solid diameter, and CT values of ground-glass nodules (GGN) were analyzed. Pearson’s chi-square test, Fisher’s exact test and One-way ANOVA were adopted tocomparebetweengroups. Receiver operating characteristic (ROC) analysis wereperformedto assess its value for prediction and diagnosis. Results: Patients with IAC were significantly elder than those in AIS or MIA group,and more MIA patients had a smoking history than AIS and IAC. No recurrence happened in the AIS and MIA groups, while 4.3% recurrences were confirmed in the IAC group. As for TSCT variables, we found AIS group showed dominantly higher 91.07%PGGN pattern and 87.50% round/oval nodules than that in MIA and IAC group. In contrast, MIA group showed more cases with undefined border and vascular convergence than AIS and IAC group. Importantly, IAC group uniquely showed higher frequency of pleural invasion compared with MIA and AIS group. The majority of patients (82.1%) in IAC group showed ≥ 50% solid proportion. We found diameter and solid diameter of the lesions were notably larger in the IAC group compared with AIS and MIA groupin quantitative aspect. In addition, for MGGNs, the CT values of ground-glass opacity (GGO) and ground-glass opacity solid portion (GGO-solid) were both higher in the IAC group than AIS and MIA. Finally, we also observed that smooth margin took a dominant proportion in the AIS group while most cases in the IAC group had a lobulate margin. Patients in MIA and IAC group shared higher level of air bronchograms and vacuole signs than AIS group. Conclusions: The unique features in different groups identified by TSCT had diagnosis value for lung adenocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document